Ovid Therapeutics Inc.
OVID- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001636651
No open-market purchases or sales by Ovid Therapeutics Inc. insiders were filed in the last 90 days; 130 institutions reported holding it in 13F filings for Q2 2026, worth $395.5M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Ovid Therapeutics Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 103 | 1 | 130 | +28 |
| Shares | 105.1M | 10.7M | 147.0M | +52.6M (+55.8%) |
| Value | $233.2M | $23.7M | $395.5M | +$186.0M (+88.8%) |
1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (46)
Institutions that held Ovid Therapeutics Inc. at the end of Q2 2026 but not at the end of Q1 2026.
Sold out (18)
Institutions that held Ovid Therapeutics Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Blue Owl Capital Holdings LP | 1,904,666 | $4.23M |
| Marshall Wace, LLP | 917,733 | $2.04M |
| Jane Street Group, LLC | 735,429 | $1.63M |
| Walleye Capital LLC | 443,362 | $984.3K |
| Citadel Advisors LLC | 367,902 | $816.7K |
| Simplify Asset Management Inc. | 130,813 | $290.4K |
| Gsa Capital Partners LLP | 123,969 | $275.0K |
| Quadrature Capital Ltd | 111,804 | $248.2K |
| Brevan Howard Capital Management LP | 101,759 | $225.9K |
| Omers Administration Corp | 100,100 | $222.2K |
| Qube Research & Technologies Ltd | 94,301 | $209.3K |
| Axq Capital, LP | 85,411 | $189.6K |
| Diametric Capital, LP | 43,262 | $96.0K |
| Mangrove Partners | 27,294 | $60.6K |
| Prelude Capital Management, LLC | 10,951 | $24.3K |
| Simplex Trading, LLC | 3,674 | $8.16K |
| Advisory Services Network, LLC | 219 | $486 |
| Sound Income Strategies, LLC | 6 | $13 |
Not filed for Q2 2026 yet (1)
Institutions that held Ovid Therapeutics Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Janus Henderson Group PLC | 10,714,000 | $23.7M |